United Therapeutics Corporation

NASDAQ:UTHR

Biotechnology

Healthcare
$577.34 -3.27%

-$18.01 today

Market cap
$24.59B
Beta
0.57
P/E (TTM)
18.0
EPS (TTM)
$29.60
52W Low $272.12High $609.35

Volume 0.42M

Average 0.52M

UTHR Income Before Tax

Profit after all operating and non-operating items but before income tax.

United Therapeutics CorporationNASDAQ: UTHR

Income Before Tax · Q2 FY2026 · quarter ended Jun 2026

Income before tax declines year over year

Q2 FY2026 income before tax of $372.7M fell 8.7% year over year, behind the -2.7% change in trailing-twelve-month income before tax. Sequentially, it rose 17.1% from the prior quarter. Over 3 fiscal years it compounded at +21.7% a year.

Context

  • Income before tax amounted to 53.9% of revenue in FY2025, up 0.4 pp from a year earlier.
  • Income before tax increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -8.7% toward the trailing-twelve-month pace of -2.7%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$372.7M+17.1% QoQ
Last fiscal yearDec 2025
$1.71B+11.4% YoY
LTMJun 2026
$1.57B-2.7% YoY
Income Before Tax past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-8.7%——
1 year+11.4%——
3-year CAGR+21.7%——
5-year CAGR——
10-year CAGR——

Income Before Tax history

USD · from the income statement

Latest · FY2025
1.71B USD
Year-over-year change
+11.4%
4-year CAGR
+30.3%

Income Before Tax vs competitors

How UTHR compares with its peers on the latest reported figures

  • UTHR's LTM Jun 2026 income before tax of $1.57B is the highest of the 5 companies compared; the peer median is -$105.34M.
  • Its year-over-year change of -2.7% is the 3rd highest of 5, against a peer median of -11.9%.
  • Income before tax amounts to 49.9% of revenue for UTHR, versus a peer median of 33.2%.
UTHR Competitors Peer median
Income Before Tax for UTHR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
UTHRUnited Therapeutics CorporationLTM Jun 2026$1.57B -2.7%+21.7%49.9%
LQDALiquidia CorporationLTM Jun 2026$149.5M +205.7%—33.2%
IKTInhibikase Therapeutics, Inc.LTM Mar 2026-$50.96M -39.4%——
TVTXTravere Therapeutics, Inc.LTM Sep 2026-$159.72M -80.4%—24.5%
INSMInsmed IncorporatedLTM Jun 2026-$869.11M +15.6%—76.4%
Peer median (excluding UTHR) -$105.34M-11.9%—33.2%

Competitors are the stored peer set for UTHR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.69B1.94B2.33B2.88B3.18B
Cost of Revenue122.5M146.7M257.5M309.7M384.4M
Gross Profit1.56B1.79B2.07B2.57B2.8B
Gross Margin92.7%92.4%88.9%89.2%87.9%
Research & Development540.1M322.9M408M481M550M
Selling, General & Admin467M487M477.1M638.6M731.1M
Operating Expenses1.01B809.9M885.1M1.19B1.28B
Depreciation & Amortization49.9M51.3M53.2M72.5M85.6M
EBITDA736.8M1.04B1.39B1.65B1.82B
EBITDA Margin43.7%53.7%59.6%57.5%57.2%
Operating Income555.9M979.7M1.18B1.38B1.52B
Operating Margin33.0%50.6%50.9%47.9%47.7%
Interest Income16.7M45.2M162.7M199.1M192M
Interest Expense18.6M32.4M59.3M42.9M19.5M
Other Income / Expenses38M(29.1M)89.4M162M196.7M
Income Before Tax593.9M950.6M1.27B1.54B1.71B
Pre-Tax Margin35.2%49.1%54.7%53.5%53.9%
Income Tax Expense118.1M223.3M289.5M343.9M379.2M
Net Income475.8M727.3M984.8M1.2B1.33B
Net Margin28.2%37.6%42.3%41.5%41.9%
EPS (Basic)10.6015.9821.0426.4430.13
EPS (Diluted)10.0615.0019.8124.6427.86
Weighted Avg Shares44.9M45.5M46.8M45.2M44.3M
Weighted Avg Shares (Diluted)47.3M48.5M49.7M48.5M47.9M

United Therapeutics Corporation

NASDAQ:UTHR

Intrinsic Alpha fair value

Locked

Current Price

$577.34

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.